# Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis

> **NCT02019056** · PHASE2 · COMPLETED · sponsor: **PharmaKing** · enrollment: 90 (actual)

## Conditions studied

- Alcoholic Fatty Liver Disease
- Alcoholic Hepatitis

## Interventions

- **DRUG:** Placebo /bid P.O
- **DRUG:** MG-1
- **DRUG:** MG-2 : MG1000mg, Placebo /bid P.O
- **DRUG:** metadoxine

## Key facts

- **NCT ID:** NCT02019056
- **Lead sponsor:** PharmaKing
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 90 (ACTUAL)
- **Last updated:** 2015-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02019056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02019056, "Efficacy and Safety of MG in the Patients With Alcoholic Fatty Liver Disease and Alcoholic Hepatitis". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT02019056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*